Who are metformin and liraglutide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Metformin XR plus liraglutide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/metformin-and-liraglutide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

metformin and liraglutide — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

metformin and liraglutide (metformin and liraglutide) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Biguanide + GLP-1 receptor agonist combination. Area: Diabetes.

marketed Biguanide + GLP-1 receptor agonist combination AMP-activated protein kinase (metformin); GLP-1 receptor (liraglutide) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

metformin and liraglutide (metformin and liraglutide) — University Medical Centre Ljubljana. Metformin reduces hepatic glucose production and improves insulin sensitivity, while liraglutide stimulates insulin secretion and suppresses glucagon in a glucose-dependent manner via GLP-1 receptor activation.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
metformin and liraglutide TARGET	metformin and liraglutide	University Medical Centre Ljubljana	marketed	Biguanide + GLP-1 receptor agonist combination	AMP-activated protein kinase (metformin); GLP-1 receptor (liraglutide)
Metformin XR plus liraglutide	Metformin XR plus liraglutide	Woman's	phase 3	Biguanide + GLP-1 receptor agonist combination	AMPK (metformin); GLP-1 receptor (liraglutide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Biguanide + GLP-1 receptor agonist combination class)

University Medical Centre Ljubljana · 1 drug in this class
Woman's · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). metformin and liraglutide — Competitive Intelligence Brief. https://druglandscape.com/ci/metformin-and-liraglutide. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab